Information Provided By: 
Fly News Breaks for March 12, 2019
INO
Mar 12, 2019 | 20:50 EDT
Piper Jaffray analyst Christopher Raymond kept his Overweight rating and $12 price target on Inovio after its Q4 results, saying the management's update also gave him "more granularity" on the timing of Phase 3 Reveal 1 and 2 trials. The analyst notes that his current model only accounts for VGX-3100 opportunity in cervical dysplasia, but he sees additional updates for VGX-3100 and immuno-oncology candidates in the second half of 2019 also potentially serving as value-creating catalysts for Inovio stock.
News For INO From the Last 2 Days
There are no results for your query INO
